Immunization with a P53 synthetic long peptide vaccine induces P53‐specific immune responses in ovarian cancer patients, a phase II trial

No abstract is available for this paper.

• Publication year

  2009

• Venue

  International Journal of Cancer

• Publication date

  2009-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/ijc.24597PMID 19621448
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Global cancer statistics

  2011cited by this paper
• Induction of p53-Specific Immunity by a p53 Synthetic Long Peptide Vaccine in Patients Treated for Metastatic Colorectal Cancer

  2009cited by this paper
• Both Germ Line and Somatic Genetics of the p53 Pathway Affect Ovarian Cancer Incidence and Survival

  2008cited by this paper
• Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1.

  2008cited by this paper
• Human papilloma virus specific T cells infiltrating cervical cancer and draining lymph nodes show remarkably frequent use of HLA‐DQ and –DP as a restriction element

  2008cited by this paper
• Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines

  2008cited by this paper
• Self-tolerance does not restrict the CD4+ T-helper response against the p53 tumor antigen.

  2008influential reference
• Induction of Tumor-Specific CD4+ and CD8+ T-Cell Immunity in Cervical Cancer Patients by a Human Papillomavirus Type 16 E6 and E7 Long Peptides Vaccine

  2008influential reference
• Survival of ovarian cancer patients overexpressing the tumour antigen p53 is diminished in case of MHC class I down-regulation.

  2008cited by this paper
• Allogeneic Granulocyte Macrophage Colony-Stimulating Factor–Secreting Tumor Immunotherapy Alone or in Sequence with Cyclophosphamide for Metastatic Pancreatic Cancer: A Pilot Study of Safety, Feasibility, and Immune Activation

  2008cited by this paper
• Skin reactions to human papillomavirus (HPV) 16 specific antigens intradermally injected in healthy subjects and patients with cervical neoplasia

  2008cited by this paper
• Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy

  2008cited by this paper
• Phase I Immunotherapeutic Trial with Long Peptides Spanning the E6 and E7 Sequences of High-Risk Human Papillomavirus 16 in End-Stage Cervical Cancer Patients Shows Low Toxicity and Robust Immunogenicity

  2008influential reference
• Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer

  2008cited by this paper
• P53‐specific T cell responses in patients with malignant and benign ovarian tumors: Implications for p53 based immunotherapy

  2007influential reference
• Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients

  2007cited by this paper
• Interleukin-2 administration alters the CD4+FOXP3+ T-cell pool and tumor trafficking in patients with ovarian carcinoma.

  2007cited by this paper
• Increased frequencies of CD8+ T lymphocytes recognizing wild‐type p53‐derived epitopes in peripheral blood correlate with presence of epitope loss tumor variants in patients with hepatocellular carcinoma

  2006cited by this paper
• Combination of p53 Cancer Vaccine with Chemotherapy in Patients with Extensive Stage Small Cell Lung Cancer

  2006cited by this paper
• Antibody immunity to the p53 oncogenic protein is a prognostic indicator in ovarian cancer.

  2006cited by this paper
• Factors influencing p53 expression in ovarian cancer as a biomarker of clinical outcome in multicentre studies

  2006cited by this paper
• Improved peptide vaccine strategies, creating synthetic artificial infections to maximize immune efficacy.

  2006cited by this paper
• Novel therapeutic agents in ovarian cancer.

  2006cited by this paper
• Immunologic aspect of ovarian cancer and p53 as tumor antigen

  2005cited by this paper
• The bone marrow: a nest for migratory memory T cells.

  2005cited by this paper
• Global Cancer Statistics, 2002

  2005cited by this paper
• Vaccination with p53-peptide–pulsed dendritic cells, of patients with advanced breast cancer: report from a phase I study

  2004cited by this paper
• Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

  2004influential reference
• Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.

  2003cited by this paper
• Magnitude and polarization of P53‐specific T‐helper immunity in connection to leukocyte infiltration of colorectal tumors

  2003cited by this paper
• Established Human Papillomavirus Type 16-Expressing Tumors Are Effectively Eradicated Following Vaccination with Long Peptides1

  2002cited by this paper
• Induction of p53-specific immune responses in colorectal cancer patients receiving a recombinant ALVAC-p53 candidate vaccine.

  2002cited by this paper
• Frequencies of tetramer+ T cells specific for the wild-type sequence p53(264-272) peptide in the circulation of patients with head and neck cancer.

  2002cited by this paper
• Effective therapeutic anticancer vaccines based on precision guiding of cytolytic T lymphocytes

  2002cited by this paper
• Antitumor efficacy of wild-type p53-specific CD4(+) T-helper cells.

  2002cited by this paper
• Long lasting p53‐specific T cell memory responses in the absence of anti‐p53 antibodies in patients with resected primary colorectal cancer

  2001cited by this paper
• Clinical significance of serum and ascitic p53 autoantibodies in epithelial ovarian carcinoma

  2000cited by this paper
• The Use of HLA A2.1/p53 Peptide Tetramers to Visualize the Impact of Self Tolerance on the TCR Repertoire1

  2000cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors

  2000cited by this paper
• p53: A Potential Target Antigen for Immunotherapy of Cancer

  2000cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

  2000cited by this paper
• Autoimmunity against p53 predicts invasive cancer with poor survival in patients with an ovarian mass

  2000cited by this paper
• p53 Antibodies in the sera of patients with various types of cancer: a review.

  2000cited by this paper
• Assessment of the prognostic relevance of serum anti-p53 antibodies in epithelial ovarian cancer.

  1999cited by this paper
• Humoral p53 antibody response is a prognostic parameter in ovarian cancer.

  1999cited by this paper
• The Central Role of CD4+ T Cells in the Antitumor Immune Response

  1998cited by this paper
• Tolerance to p53 by A2.1-restricted Cytotoxic T Lymphocytes

  1997cited by this paper
• Unique tumor antigens redefined as mutant tumor-specific antigens.

  1996cited by this paper
• Primary proliferative T cell response to wild‐type p53 protein in patients with breast cancer

  1995cited by this paper
• Cancer of the ovary.

  1994cited by this paper
• Cancer of the ovary.

  1993cited by this paper
• Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells.

  1991cited by this paper

• The search for a TNBC vaccine: the guardian vaccine

  2025cites this paper
• Montanide ISA-51: a promising adjuvant in cancer vaccine immunotherapy

  2025cites this paper
• The bright side of chemistry: Exploring synthetic peptide‐based anticancer vaccines

  2024cites this paper
• p53 at the crossroads of tumor immunity

  2024cites this paper
• Exploring the Potential of Natural Killer Cell-Based Immunotherapy in Targeting High-Grade Serous Ovarian Carcinomas

  2024cites this paper
• Pro-inflammatory Cytokines and CXC Chemokines as Game-Changer in Age-Associated Prostate Cancer and Ovarian Cancer: Insights from Preclinical and Clinical Studies' Outcomes.

  2024cites this paper
• Vaccines targeting p53 mutants elicit anti-tumor immunity.

  2024cites this paper
• On-Site Stimulation of Dendritic Cells by Cancer-Derived Extracellular Vesicles on a Core–Shell Nanowire Platform

  2024cites this paper
• Maveropepimut-S, a DPX-Based Immune-Educating Therapy, Shows Promising and Durable Clinical Benefit in Patients with Recurrent Ovarian Cancer, a Phase II Trial

  2023cites this paper
• The Challenges and Prospects of p53-Based Therapies in Ovarian Cancer

  2023cites this paper
• Exploring the tumor immune microenvironment in ovarian cancer: a way-out to the therapeutic roadmap

  2023cites this paper
• Protein ubiquitination in ovarian cancer immunotherapy: The progress and therapeutic strategy

  2023cites this paper
• Induction of broad multifunctional CD8+ and CD4+ T cells by hepatitis B virus antigen-based synthetic long peptides ex vivo

  2023cites this paper
• Peptide Vaccines as Therapeutic and Prophylactic Agents for Female-Specific Cancers: The Current Landscape

  2023cites this paper
• Immunotherapeutic Approaches in Ovarian Cancer

  2023cites this paper
• Immunotherapy in Ovarian Cancer

  2022cites this paper
• In Silico Model Estimates the Clinical Trial Outcome of Cancer Vaccines

  2021cites this paper
• Barriers to Immunotherapy in Ovarian Cancer: Metabolic, Genomic, and Immune Perturbations in the Tumour Microenvironment

  2021cites this paper
• Evolution of Cancer Vaccines—Challenges, Achievements, and Future Directions

  2021cites this paper
• Clinical and Immunological Effects of p53-Targeting Vaccines

  2021cites this paper
• Ovarian cancer: Targeted therapies and mechanisms of resistance

  2021cites this paper
• The Role of Peptide-Based Tumor Vaccines on Cytokines of Adaptive Immunity: A Review

  2021cites this paper
• p53, cancer and the immune response

  2020cites this paper
• Immunotherapeutic strategies for the treatment of ovarian cancer: current status and future direction

  2020cites this paper
• Development of Therapeutic Vaccines for Ovarian Cancer

  2020influential citation
• Enhancing Delivery of Small‐Molecule‐ and Cell‐Based Therapies for Ovarian Cancer Using Advanced Delivery Strategies

  2020cites this paper
• First‐in‐human study of the cancer peptide vaccine TAS0313 in patients with advanced solid tumors

  2020cites this paper
• Integrating context of tumor biology and vaccine design to shape multidimensional immunotherapies

  2020cites this paper
• Evaluación del aislamiento Rotaviral TRUY como potencial agente oncolítico en células tumorales de ovario

  2020cites this paper
• Safety, immunogenicity, and clinical efficacy of durvalumab in combination with folate receptor alpha vaccine TPIV200 in patients with advanced ovarian cancer: a phase II trial

  2020cites this paper
• Immunotherapy of gynecological cancers.

  2019cites this paper
• Next Generation Sequencing (NGS) in Relapsed/Refractory HPV Negative Head and Neck Squamous Cell Carcinoma (HNSCC) Reveals Diverse Genomic Alterations and Potential Targets of Therapy

  2019cites this paper
• Immunotherapy for Gynecologic Cancer: Current Applications and Future Directions

  2019cites this paper
• Strategies for developing and optimizing cancer vaccines

  2019cites this paper
• Overview of Current Immunotherapies Targeting Mutated KRAS Cancers.

  2019cites this paper
• Therapeutic cancer vaccine: building the future from lessons of the past

  2018cites this paper
• Linking T cell epitopes to a common linear B cell epitope: A targeting and adjuvant strategy to improve T cell responses

  2018cites this paper
• Therapeutic cancer vaccines: From initial findings to prospects.

  2018cites this paper
• Therapeutic Potential of Tumor Suppressors in Treating Breast Cancer

  2018cites this paper
• p53-Reactive T Cells Are Associated with Clinical Benefit in Patients with Platinum-Resistant Epithelial Ovarian Cancer After Treatment with a p53 Vaccine and Gemcitabine Chemotherapy

  2018cites this paper
• Redox reactions in cancer: impact and regulation

  2018cites this paper
• Antigen-specific active immunotherapy for ovarian cancer.

  2018cites this paper
• Immunostimulation and Immunosuppression: Nanotechnology on the brink

  2018cites this paper
• The Future in Ovarian Cancer: Advances in Immunotherapies

  2017cites this paper
• Ovarian Cancer: New Targets and Future Directions

  2017cites this paper
• Immunology and Immunotherapy in Ovarian Cancer

  2017cites this paper
• Immunotherapy in ovarian cancer.

  2017cites this paper
• Cancer vaccine therapy based on peptides

  2017cites this paper
• Still Laughing Failures behind the Windows of Cancer Therapeutic Strategies

  2017cites this paper
• Personalized peptide vaccines for cancer therapy: current progress and state of the art

  2017cites this paper
• Efficacy of glypican-3-derived peptide vaccine therapy on the survival of patients with refractory ovarian clear cell carcinoma

  2016cites this paper
• Dendritic cell-based immunotherapy

  2016cites this paper
• Adjuvant Autologous Melanoma Vaccine for Macroscopic Stage III Disease: Survival, Biomarkers, and Improved Response to CTLA-4 Blockade

  2016cites this paper
• Contribution des effets ciblés et non ciblés en radioimmunothérapie alpha et Auger de carcinoses péritonéales

  2016cites this paper
• High Aspect Ratio Viral Nanoparticles for Cancer Therapy

  2016cites this paper
• Leveraging immunotherapy for the treatment of gynecologic cancers in the era of precision medicine.

  2016cites this paper
• Personalized Peptide Vaccine

  2016cites this paper
• The Role of the Immune System in Ovarian Cancer and Implications on Therapy

  2016influential citation
• Cancer Vaccines in Ovarian Cancer: How Can We Improve?

  2016cites this paper
• The present status and future prospects of peptide-based cancer vaccines.

  2016cites this paper
• Chemoresistance and targeted therapies in ovarian and endometrial cancers

  2016cites this paper
• Prospect and progress of personalized peptide vaccinations for advanced cancers

  2016cites this paper
• Antitumor dendritic cell-based vaccines: lessons from 20 years of clinical trials and future perspectives.

  2016cites this paper
• Molecular and functional analysis of the tumour antigen T21

  2015cites this paper
• Cellular immunotherapy in ovarian cancer: Targeting the stem of recurrence.

  2015cites this paper
• A phase 1/2 study combining gemcitabine, Pegintron and p53 SLP vaccine in patients with platinum-resistant ovarian cancer

  2015cites this paper
• Immunotherapeutic approaches to ovarian cancer treatment

  2015influential citation
• SYNTHETIC LONG PEPTIDE DERIVED FROM M. TUBERCULOSIS LATENCY ANTIGEN 1

  2015cites this paper
• Molecular mechanisms of apoptosis and roles in cancer development and treatment.

  2015cites this paper
• Assessment of immunological responses to tumour antigens relevant to the development of therapeutic cancer vaccines

  2015cites this paper
• Emerging immunotherapies in ovarian cancer.

  2015cites this paper
• Synthetic Long Peptide Derived from Mycobacterium tuberculosis Latency Antigen Rv1733c Protects against Tuberculosis

  2015cites this paper
• Targeting p53 Tumor Suppressor for AML Therapy

  2015cites this paper
• Principles of Targeted Immunotherapy

  2015cites this paper
• Therapeutic targeting of tumor suppressor genes

  2015cites this paper
• Ovarian Cancer from an Immune Perspective

  2014cites this paper
• Melanocortin 1 Receptor-derived peptides are efficiently recognized by cytotoxic T lymphocytes from melanoma patients.

  2014cites this paper
• Evaluation of tumor response to cytokine-induced killer cells therapy in malignant solid tumors

  2014cites this paper
• Cross-Presentation of Synthetic Long Peptides by Human Dendritic Cells: A Process Dependent on ERAD Component p97/VCP but Not sec61 and/or Derlin-1

  2014cites this paper
• Immunosuppression through constitutively activated NF-κB signalling in human ovarian cancer and its reversal by an NF-κB inhibitor

  2014cites this paper
• Peptide-Based Vaccination and Induction of CD8+ T-Cell Responses Against Tumor Antigens in Breast Cancer

  2014cites this paper
• The External Quality Assurance Oversight Laboratory (EQAPOL) proficiency program for IFN-gamma enzyme-linked immunospot (IFN-γ ELISpot) assay.

  2014cites this paper
• Personalized peptide vaccine for treatment of advanced cancer.

  2014cites this paper
• Feasibility study of personalized peptide vaccination for recurrent ovarian cancer patients

  2014cites this paper
• Overcoming immunosuppression to enhance a p53MVA vaccine

  2014cites this paper
• Immunotherapy for ovarian cancer: recent advances and perspectives

  2014cites this paper
• The need for improvement of the treatment of advanced and metastatic cervical cancer, the rationale for combined chemo-immunotherapy.

  2014cites this paper
• Scientific contributions toward successful cancer immunotherapy in The Netherlands.

  2014cites this paper
• Recent progress in peptide vaccination in cancer with a focus on non-small-cell lung cancer

  2014cites this paper
• Polymer functionalized single walled carbon nanotubes mediated drug delivery of gliotoxin in cancer cells.

  2014cites this paper
• Revolutionary impact of nanovaccines on immunotherapy

  2014cites this paper
• Scientific contributions toward successful cancer immunotherapy in

  2014cites this paper
• [Immunotherapy in epithelial ovarian carcinoma: hope and reality].

  2014cites this paper
• Antigen-specific active immunotherapy for ovarian cancer.

  2014cites this paper
• Peptide and Protein-Based Cancer Vaccines

  2013cites this paper
• Vaccine delivery carriers: insights and future perspectives.

  2013cites this paper
• Dendritic-cell-based therapeutic cancer vaccines.

  2013cites this paper
• Chapter 16 – Comprehensive Immunomonitoring to Guide the Development of Immunotherapeutic Products for Cancer

  2013cites this paper
• Immature, Semi-Mature, and Fully Mature Dendritic Cells: Toward a DC-Cancer Cells Interface That Augments Anticancer Immunity

  2013cites this paper
• Dendritic cell immunotherapy

  2013cites this paper